Gabrielle Bouchard
Overview
Explore the profile of Gabrielle Bouchard including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
11
Citations
739
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Nassar A, Abou Alaiwi S, Baca S, Adib E, Corona R, Seo J, et al.
Nat Commun
. 2023 Jan;
14(1):346.
PMID: 36681680
While the mutational and transcriptional landscapes of renal cell carcinoma (RCC) are well-known, the epigenome is poorly understood. We characterize the epigenome of clear cell (ccRCC), papillary (pRCC), and chromophobe...
2.
Gan C, Huang J, Pan E, Xie W, Schmidt A, Labaki C, et al.
Eur Urol Oncol
. 2022 Nov;
6(2):204-211.
PMID: 36328934
Background: There is a paucity of data on the safety of cabozantinib use in combination with radiotherapy. Objective: To report the practice patterns, safety, and efficacy of cabozantinib with radiotherapy...
3.
Bakouny Z, Sadagopan A, Ravi P, Metaferia N, Li J, Abuhammad S, et al.
Cell Rep
. 2022 Jan;
38(1):110190.
PMID: 34986355
Translocation renal cell carcinoma (tRCC) is a poorly characterized subtype of kidney cancer driven by MiT/TFE gene fusions. Here, we define the landmarks of tRCC through an integrative analysis of...
4.
Bhalla S, Bakouny Z, Schmidt A, Labaki C, Steinharter J, Tremblay D, et al.
Lung Cancer
. 2021 Aug;
160:78-83.
PMID: 34461400
Introduction: Patients with lung cancer (LC) are susceptible to severe outcomes from COVID-19. This study evaluated disruption to care of patients with LC during the COVID-19 pandemic. Methods: The COVID-19...
5.
Braun D, Street K, Burke K, Cookmeyer D, Denize T, Pedersen C, et al.
Cancer Cell
. 2021 Mar;
39(5):632-648.e8.
PMID: 33711273
The tumor immune microenvironment plays a critical role in cancer progression and response to immunotherapy in clear cell renal cell carcinoma (ccRCC), yet the composition and phenotypic states of immune...
6.
Bi K, He M, Bakouny Z, Kanodia A, Napolitano S, Wu J, et al.
Cancer Cell
. 2021 Mar;
39(5):649-661.e5.
PMID: 33711272
Immune checkpoint blockade (ICB) results in durable disease control in a subset of patients with advanced renal cell carcinoma (RCC), but mechanisms driving resistance are poorly understood. We characterize the...
7.
Bakouny Z, Braun D, Shukla S, Pan W, Gao X, Hou Y, et al.
Nat Commun
. 2021 Feb;
12(1):808.
PMID: 33547292
Sarcomatoid and rhabdoid (S/R) renal cell carcinoma (RCC) are highly aggressive tumors with limited molecular and clinical characterization. Emerging evidence suggests immune checkpoint inhibitors (ICI) are particularly effective for these...
8.
Tripathi A, Lin E, Xie W, Flaifel A, Steinharter J, Stern Gatof E, et al.
J Immunother Cancer
. 2020 Nov;
8(2).
PMID: 33177176
Background: CD73-adenosine signaling in the tumor microenvironment is immunosuppressive and may be associated with aggressive renal cell carcinoma (RCC). We investigated the prognostic significance of CD73 protein expression in RCC...
9.
Schmidt A, Bakouny Z, Bhalla S, Steinharter J, Tremblay D, Awad M, et al.
Cancer Cell
. 2020 Nov;
38(6):769-770.
PMID: 33176161
No abstract available.
10.
Author Correction: Detection of renal cell carcinoma using plasma and urine cell-free DNA methylomes
Nuzzo P, Berchuck J, Korthauer K, Spisak S, Nassar A, Abou Alaiwi S, et al.
Nat Med
. 2020 Sep;
26(10):1663.
PMID: 32895574
An amendment to this paper has been published and can be accessed via a link at the top of the paper.